Quratis is at the forefront of innovative healthcare solutions, focusing on the development of advanced vaccines and therapeutic platforms. Their core technologies include the Adjuvant Platform and Cell Therapy Platform, which are designed to enhance immune responses and improve the efficacy of vaccines. Notably, Quratis is actively working on vaccines for tuberculosis (QTP101) and COVID-19 (QTP104), utilizing substances that boost both cellular and fluid immune responses. Additionally, the company has developed a Cell/Bacterial Penetrating Peptide (CPP) platform, which facilitates the delivery of various therapeutic agents, including antibiotics, antivirals, and anticancer drugs.

In addition to their vaccine initiatives, Quratis is engaged in custom manufacturing services through their Contract Manufacturing Organization (CMO) and Contract Development and Manufacturing Organization (CDMO) divisions. These services encompass the development of biopharmaceutical raw materials and the formulation of finished pharmaceutical products. The company also explores innovative technologies such as Peptide Nucleic Acid (PNA), a synthetic analogue of DNA, which has potential applications in various therapeutic areas. Through collaborations with organizations like IDRI, Quratis aims to contribute significantly to global healthcare advancements.

South Korea

Quratis Inc operates as a developer of vaccines and therapies designed to treat tuberculosis. The company develops youth and adults tuberculosis vaccines, messenger ribonucleic acids, and other related immune-related vaccines.

Cancer

Infectious Diseases

Quratis

QuaC lnj (Ascorbic acid)

Biologics

Tuberculosis

QTP101

Vaccines

COVID-19

QTP104

Schistosomiasis

QTP105

QTP102

Scrub typhus

Vaccine

QTP705

Methicillin-resistant staphylococcus aureus

Peptide Nucleic acid

Cell penetrating peptide; TB target peptide

Peptide nucleic acid

Drug

Antiviral Therapies

Therapeutic

Quratis

Company Details